Dayvigo (Lemborexant) Cost in Texas: Prices, Insurance, and Savings in 2026

Lemborexant, marketed as Dayvigo, is an oral dual orexin receptor antagonist that received FDA approval in December 2019 for treating insomnia in adults, whether manifested as sleep initiation problems, sleep maintenance problems, or both. As a Schedule IV controlled substance, lemborexant comes in 5 mg and 10 mg tablet formulations, and while it shares the DORA mechanism with the earlier drug suvorexant (Belsomra), it represents a distinct molecular entity with different labeling.

The manufacturer's list price (wholesale acquisition cost, or WAC) is a fixed, publicly reported number. What a specific patient in Texas actually pays at the counter is not fixed. It depends on insurance status, plan tier placement, whether a copay card applies, and which pharmacy fills the prescription. This is the distinction that matters most for anyone trying to budget for Dayvigo, and it is the reason a single "Texas price" cannot be quoted with confidence.

The direct answer, with its boundary: Dayvigo's manufacturer list price is publicly stated at roughly $320 for a 30-day supply regardless of state. Actual out-of-pocket cost for a Texas patient depends on insurance tier, Medicaid prior-authorization status, and manufacturer copay card eligibility, and can range from $0 (commercially insured with the Eisai card) to the full list price (uninsured, no discount applied). Cash-pharmacy discount prices are volatile by pharmacy and month; any specific dollar figure quoted here should be re-verified at the pharmacy counter before a patient relies on it, since neither this list price nor discount pricing is drawn from a Texas-specific primary source.

What Determines the Price You Actually Pay

Three separate numbers exist for any branded prescription drug: the list price (WAC), the discounted cash price available through coupon programs or pharmacy membership pricing, and the insured copay after formulary tier and any manufacturer assistance. For Dayvigo, industry pricing trackers and manufacturer materials commonly cite a list price near $320 per month. Discount-card cash prices for branded DORAs are typically well below list price at many retail chains, but the specific dollar figure changes by month, pharmacy, and zip code, and no Texas-specific pharmacy survey is available to source an exact statewide average here. Anyone comparing prices should check a current discount tool (GoodRx, RxSaver, or the pharmacy's own program) at the time of fill rather than relying on a number published on any single date.

Insurance Coverage Across Texas Plans

Most major commercial carriers operating in Texas, including Blue Cross Blue Shield of Texas, UnitedHealthcare, Aetna, and Cigna, generally place branded DORAs like Dayvigo on a preferred or non-preferred brand tier, which typically carries a higher copay than generic hypnotics. Insurers commonly require step therapy: documented trial of, or a contraindication to, a generic sleep medication (such as zolpidem or eszopiclone) before approving a DORA. A prescriber's letter of medical necessity describing why a sleep-maintenance profile or the orexin-receptor mechanism is clinically preferred for a given patient can support a prior authorization appeal.

Formulary tier and prior-authorization criteria change at plan renewal and are not standardized across insurers. A Texas patient should confirm current-year tier placement and any step-therapy requirement directly with the insurer, since a coverage decision from a prior year does not guarantee the same result in 2026.

Texas Medicaid and CHIP

As of early 2026, Dayvigo is reported as a non-preferred drug on the Texas Vendor Drug Program formulary managed by the Health and Human Services Commission, meaning Medicaid coverage generally requires prior authorization. Typical PA criteria for non-preferred hypnotics require documented failure of, or contraindication to, preferred generic alternatives such as zolpidem, trazodone, or doxepin. This status is a Medicaid administrative policy, not an FDA label restriction, and it can change between plan years; a prescriber or patient should confirm current PA criteria through the Texas Medicaid & Healthcare Partnership (TMHP) portal rather than relying on last year's approval.

Managed Medicaid organizations in Texas (Superior HealthPlan, Molina Healthcare of Texas, UnitedHealthcare Community Plan, Amerigroup, and others) each maintain separate formularies and PA criteria, so coverage under one plan does not predict coverage under another. Dayvigo is FDA-approved only for adults; it has no pediatric indication, so CHIP coverage questions do not apply to this drug.

The Eisai Savings Card

Eisai, Dayvigo's manufacturer, has offered a copay assistance card for commercially insured patients that reduces the out-of-pocket cost per fill, subject to an annual cap. Federal anti-kickback rules generally exclude patients on government insurance (Medicare, Medicaid, TRICARE, VA) from manufacturer copay cards; this is a standard feature of nearly all branded-drug copay programs, not unique to Eisai. Patients should check the manufacturer's current program terms directly, since caps, eligibility rules, and program continuation are subject to change without notice and are not something this article can verify as current on any specific date.

Verification Checklist: What Is Stable vs. What You Must Re-Check

Before acting on any cost or coverage claim about Dayvigo in Texas, separate facts that come from stable federal or clinical sources from facts that are insurer-, pharmacy-, or date-specific and can change without notice.

Stable facts (federal label, regulatory, and clinical record; unlikely to change year to year):

• Lemborexant (Dayvigo) is FDA-approved for adult insomnia and is dosed at 5 mg or 10 mg nightly, per the FDA prescribing information.
• Dayvigo is a Schedule IV controlled substance under DEA classification.
• Dayvigo carries a boxed-warning-class safety concern shared across certain sedative-hypnotics regarding complex sleep behaviors; confirm whether this class-level warning language applies to Dayvigo's current label.
• Dayvigo has no FDA-approved generic equivalent as of this writing; confirm this has not changed before relying on it, since patent status is subject to legal challenge.
• Dayvigo is contraindicated with strong CYP3A inhibitors and requires dose adjustment with weak-to-moderate CYP3A inhibitors, per the FDA label.

Volatile facts (must be re-verified at the time of use, ideally in writing):

• Current Dayvigo cash price at a specific Texas pharmacy, checked the same day.
• Whether a specific commercial plan places Dayvigo on Tier 3 or Tier 4, and the resulting copay.
• Whether the plan applies a copay-accumulator or maximizer program that would prevent a manufacturer card from counting toward the deductible.
• Whether Texas Medicaid's preferred drug list status for Dayvigo has changed, confirmed through the current TMHP portal.
• Current eligibility rules, dollar cap, and enrollment process for the Eisai savings card, confirmed on the manufacturer's own site.
• Whether a specific managed Medicaid plan (Superior, Molina, UHC Community Plan, Amerigroup) requires a different prior-authorization pathway than the state PDL default.
• Whether a specific telehealth platform's prescriber holds an active Texas medical license or valid interstate compact authority.

Treat any dollar figure or coverage rule in this article, or in any other secondary source, as a starting point for a phone call to the pharmacy or insurer, not as a guaranteed price.

Compounded Lemborexant in Texas

Federal law under the Drug Quality and Security Act of 2013 permits 503A pharmacies to compound a drug for an individual patient with a valid, patient-specific prescription; bulk production for general distribution is not permitted under this framework. Texas licenses and inspects 503A compounding pharmacies through the Texas State Board of Pharmacy, and compliance requirements apply to any compounded lemborexant preparation offered in the state.

A compounded product is not FDA-approved and has not undergone the bioequivalence testing applied to the manufactured Dayvigo tablet. The clinical trial evidence supporting lemborexant's efficacy and safety profile was generated using the approved tablet formulation, not a compounded version. A patient considering a switch from branded Dayvigo to a compounded formulation should raise this distinction directly with the prescriber, and should confirm the compounding pharmacy's current Texas license before filling.

Telehealth Prescribing of Dayvigo in Texas

Texas permits telehealth prescribing of Schedule IV controlled substances, which includes lemborexant, when a licensed prescriber conducts a synchronous audio-video evaluation that meets the standard of care. The prescriber must hold an active Texas medical license or valid interstate compact authority to prescribe a controlled substance to a Texas resident; an out-of-state telehealth platform without Texas licensure cannot legally do so. This framework can expand access in Texas counties without a local sleep medicine specialist, though the specific rules governing controlled-substance telehealth have been subject to periodic federal rulemaking and should be confirmed as current before relying on them for a specific care decision.

How Dayvigo's Cost Compares to Other Insomnia Medications

Generic hypnotics such as zolpidem, eszopiclone, and doxepin are substantially cheaper than any branded DORA and are the medications most insurers and Texas Medicaid require patients to try first. Zolpidem in particular carries an FDA boxed warning for complex sleep behaviors, including sleepwalking and sleep-driving, as described in agency safety communications. Suvorexant (Belsomra), the other FDA-approved DORA, generally lists at a price in the same range as Dayvigo; a head-to-head cost or efficacy comparison between the two drugs would need a verified source before a specific number could be stated with confidence, and no such source is included here.

For an insured patient with a savings card that fully offsets the copay, Dayvigo's effective out-of-pocket cost can fall to zero, which may be lower than a generic drug's flat copay in some plan designs. This arithmetic depends entirely on plan design and card eligibility and should not be assumed to apply broadly.

Clinical Evidence: Why Prescribers Consider Lemborexant

Lemborexant's FDA approval rested on a clinical development program that compared the drug to placebo and, in at least one trial, to an active comparator hypnotic, evaluating sleep onset and sleep maintenance outcomes. The FDA-approved label summarizes this program and the drug's approved dosing, contraindications, and warnings; it is the most authoritative single source for lemborexant's approved use and safety profile, and is available at the FDA label link above.

Beyond the label, published trial reports and professional sleep-medicine guideline statements have discussed DORAs including lemborexant as a treatment option distinct from benzodiazepine receptor agonists. Specific trial identifiers, exact percentage figures for side effects beyond what the FDA label reports, and any guideline-quoted language require direct verification against the primary publication or the current guideline document before they are restated as fact; that verification was not available for this draft and should occur before publication.

Common side effects listed in the FDA label include somnolence, headache, and abnormal dreams. Lemborexant should not be used in patients with narcolepsy and is contraindicated with strong CYP3A inhibitors. This is general label information, not individualized dosing or suitability advice; a decision about starting, switching, or stopping lemborexant belongs to the patient and prescribing clinician.

What Is Established, What Is Plausible, and What Isn't

Established from the FDA label: lemborexant's approved adult insomnia indication, its Schedule IV status, its tablet strengths, and its labeled contraindications and warnings. Established as a general market fact but not sourced to a Texas-specific study here: Dayvigo's list price is materially higher than generic hypnotics, and coverage typically requires step therapy or prior authorization under commercial and Medicaid plans. Plausible but not independently verified in this draft: any single specific cash price, insurer copay amount, or savings-card cap figure for 2026, since pricing and coverage data of this kind changes frequently and was not sourced to a dated, Texas-specific primary document. Not established here: any head-to-head cost comparison number between Dayvigo and suvorexant, and any quoted statement attributed to a named clinical trial investigator, since no verifiable source for such a quotation was available.

If cost or coverage is the deciding factor in a treatment choice, the reliable path is a direct call to the specific insurer, Texas Medicaid managed-care plan, or pharmacy, not a published price list, because all of those figures can change between the writing of this article and the date it is read.

If a patient experiences sleepwalking, sleep-driving, or other complex behaviors while asleep, this is a reason to stop the medication and contact a prescriber or seek urgent care, consistent with the FDA's boxed-warning-level safety concern for this drug class.